Human papillomavirus infections: Epidemiology, clinical aspects and vaccines

Open Infectious Diseases Journal

Volumn 3, Issue SPEC.ISS.1, 2009, Pages 135-142

  Denny, Lynette ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877648895     PISSN: None     EISSN: 18742793     Source Type: Journal    
DOI: 10.2174/1874279301004010135     Document Type: Article

References (56)

1. Munoz N, Castellsague X, Berrington de Gonzalez A, Gissman L. HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl 3): S3/1-10.
2. Clifford GM, Galios S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-998.
3. de Sanjose S, Diaz M, Castellsague X, et al. World wide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-459.
4. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196: 1128-1136.
5. Ho GY, Beirman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.
6. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky L. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-226.
7. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Inf Dis 2008; 197: 279-282.
8. Richardson H, Kelsall G, Tellier P, et al. The natural history of ype-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12: 485-490.
9. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence and learance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis 2002; 186: 462-469.
10. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97: 577-586.
11. Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
12. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN 3 or cervical cancer. Lancet 2002; 360: 228-229.
13. Einstein M, Schiller J, Viscidi R, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9: 347-356.
14. Kjaer SK, Chackerian B, van den Brule AJC, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001; 10: 101-106.
15. Castellsague X, Ghaffaria A, Daniel RW, Bosch FX, Munoz N, Shah KV. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J Infect Dis 1997; 176: 353-361.
16. Cason J. Perinatal acquisition of cervical cancer associated papillomaviruses. Br J Obstet Gynaecol 1996; 103: 853-858.
17. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101: 645-652.
18. Armbruster-Moraes E, Ioshimoto LM, Leao E, Zugaib M. Presence of human papillomavirus DNA in amniotic fluids of pregnant women with cervical lesions. Gynecol Oncol 1994; 54: 152-158.
19. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence: mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0 Lyon: IARC Press 2004.
20. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world wide. J Pathol 1999; 189: 12-19.
21. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003; 348: 518-527.
22. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007: 121: 621-632.
23. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999; 91: 954-960.
24. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 1999; 354: 20-25.
25. Yitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60: 6027-6032.
26. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 379: 1609-1621.
27. Ho GY, Kadish AS, Burk RD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial noeoplasia. Int J Cancer 1998; 78: 281-285.
28. Morena V, Munoz N, Bosch FX, et al. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 459-467.
29. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89 (Suppl 2): S4-S12.
30. Denny L. The prevention of cervical cancer in developing countries. BJOG 2005; 112: 1204-1212.
31. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC, Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005; 294: 2173-2181.
32. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406.
33. Sankaranarayanan R, Nene B, Shastri S, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-1394.
34. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005; 353: 2158-2168.
35. Arbyn M, Sasieni P, Meijer CJLM, Duval C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24(Suppl 3): S3/78-89.
36. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. New dimensions in cervical cancer screening. Vaccine 2006; 24(Suppl 3): S3/90-97.
37. Franco EL. Primary screening fo cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003; 31: 89-96.
38. Denny LA, Wright TC Jr. Human papillomavirus testing and screening. Best Pract Res Clin Obstet Gynaecol 2005; 19: 501-515.
39. Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive cytologically negative women. Cancer 2002; 95: 2145-2151.
40. Koutsky L, Holmes K, Crichlow M, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 1272-1278.
41. Rozendal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytologically normal cervical smears. Int J Cancer 1996; 68: 766-769.
42. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-936.
43. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high risk HIV-negative women. J Natl Cancer Inst 1999; 91: 226-236.
44. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 200; 283: 1031-1037.
45. Harris TG, Burk RD, Palesky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005: 293: 1471-1476.
46. Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women. Obstet Gynecol 2008; 111: 1380-1387.
47. Singh D, Anastos K, Hoover D, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009; 199: 1851-1861.
48. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364: 1757-1765.
49. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367: 1247-1255.
50. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 372: 1645-1651.
51. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomaviurs-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
52. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 & 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
53. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to Prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
54. Lacey CJ. Therapy for genital human papilloma-virus related disease. J Clin Virol 2005; 32(Suppl 1): S82-S90.
55. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts or cervical neoplasia? A meta-analysis. Sex Trans Dis 2002; 29: 725-735.
56. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-1164.